Skip to main content
Koen van Besien on Muck Rack

Koen van Besien

As seen in: Journal of Clinical Pathology, MDPI, JAMA Oncology, Cell Press, EClinicalMedicine, Healio, HemOnc Today, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Koen

Contact Koen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records

|
By Eric Edward Irons, Keri Ann Pfeil, Jaime Perez, Jaime Pérez, Koen van Besien
| EClinicalMedicine Verified
Keywords Glucagon-like peptide 1 receptor agonist Sodium glucose cotransporter 2 inhibitor Obesity Diabetes mellitus Multiple myeloma Evidence before this study Obesity has been associated with an increased risk of certain hematologic cancers. Although the weight loss-inducing GLP-1 receptor agonists are associated with risk reduction for obesity-related cancers, it is unclear whether they also alter the risk of hematologic malignancies.
Open in Who Shared Issue with article?

High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?

|
By Koen van Besien, van Besien, Michael Daunov
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

UH Seidman Cancer Center names division chief, immunotherapy center director

|
By Koen van Besien
| HemOnc Today Verified
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center. He also will serve as director of Wesley Center for Immunotherapy, which generates chimeric antigen receptor T-cell therapies, natural killer cell therapies and other cellular-based therapies. His appointment is effective July 15.
Open in Who Shared Issue with article?
See all 9 licensed articles (10 Total)